Fingolimod Pregnancy and Breastfeeding Warnings
Fingolimod is also known as: Gilenya
Fingolimod Pregnancy Warnings
This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus. AU TGA pregnancy category: D US FDA pregnancy category: C Comments: Women of childbearing potential should be encouraged to use adequate methods of contraception during and for at least 2 months after therapy.
This drug and/or its metabolites crossed the placental barrier in animal models. Animal studies have shown teratogenicity and embryolethality including organ defects, notably persistent truncus arteriosus and ventricular septal defect. When administered during organogenesis, increased fetal malformations and embryo-fetal deaths were observed. There was reduced perinatal survival, and a neurobehavioral (learning) deficit was seen in the offspring. The receptor affected by this drug (sphingosine 1-phosphate receptor) is known to be involved in vascular formation during embryogenesis. There are no adequate and well-controlled studies in pregnant women. A pregnancy registry has been established to monitor maternal-fetal outcomes of pregnant women exposed to this drug. Physicians are encouraged to enroll pregnant patients, or pregnant women may register themselves by visiting www.gilenyapregnancyregistry.com. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Fingolimod Breastfeeding Warnings
In animal models, this drug was excreted in the milk at concentrations 2 to 3 fold higher than that found in maternal plasma. There were no effects on body weight, development, behavior, or fertility in the nursing animals. Reduced immunocompetence was seen in juvenile animals after oral administration.
Use is not recommended and a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: There is a potential for serious adverse effects in nursing infants.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.